FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2337582785> ?p ?o ?g. }

• W2337582785 endingPage "5385" @default.
• W2337582785 startingPage "5379" @default.
• W2337582785 abstract "NIBP, a novel nuclear factor-κB (NF-κB)-inducing kinase (NIK) and IκB kinase β (IKKβ) binding protein, directly interacts with NIK and IKKβ, and acts as the ʻbridgeʼ of the NF‑κB classical and alternative signaling pathways. However, its influence on epithelial‑mesenchymal transition markers in colon cancer remains to be fully elucidated. The aim of the present study was to investigate the roles of NIBP impacting on the expression of E‑cadherin, CD44 and vimentin. In the present study, the associations between NIBP and E‑cadherin, CD44 and vimentin in clinical samples were analyzed by making pairwise comparisons between normal colon tissue, non‑metastatic colon cancer tissue and metastatic colon cancer tissue. In in vitro experiments, after changing the expression of NIBP in cells, the protein expression levels of CD44, vimentin, E‑cadherin were analyzed by western blot analysis. The results revealed that the protein expression levels of NIBP, CD44 and vimentin were markedly increased, and E‑cadherin was markedly decreased, in metastatic colon cancer tissue compared with normal colon tissue and non‑metastatic colon cancer tissue. Upregulation of NIBP expression decreased the levels of E‑cadherin, whereas the downregulation of NIBP increased E‑cadherin levels, while no significant differences were observed in the levels of CD44 and vimentin. In addition, cells that were treated with the NF‑κB inhibitor, pyrrolidine dithiocarbamate (PDTC), also tended to exhibit increased levels of CD44 and vimentin expression in the NIBP upregulated expression group (29‑NIBP group) compared with the mock group, whereas the expression levels of E‑cadherin, CD44 and vimentin were similar in the NIBP downregulated expression group (116‑NIBPmir group) and the HCT116 blank control group (116‑mock group) on treatment of the cells with tumor necrosis factor‑α. These findings indicated that NIBP, E‑cadherin, CD44 and vimentin are possibly associated with metastasis in colon cancer. When the NF‑κB pathway is not subjected to any interventions, NIBP may predominantly regulate the NF‑κB classical pathway, rather than the alternative pathway. When the classical pathway was completely inhibited, NIBP was able to activate the NF‑κB alternative pathway. NIBP is therefore necessary for the interaction between the NF‑κB classical and alternative pathways. In conclusion, NIBP impacts on the expression levels of E‑cadherin, CD44 and vimentin via the NF‑κB classical and alternative pathways. Therapeutic regimens for patients with colorectal cancer may comprise NIBP inhibitors in the future." @default.
• W2337582785 created "2016-06-24" @default.
• W2337582785 creator A5006938709 @default.
• W2337582785 creator A5031810904 @default.
• W2337582785 creator A5057107704 @default.
• W2337582785 creator A5060282209 @default.
• W2337582785 creator A5084950552 @default.
• W2337582785 date "2016-04-22" @default.
• W2337582785 modified "2023-10-07" @default.
• W2337582785 title "NIBP impacts on the expression of E-cadherin, CD44 and vimentin in colon cancer via the NF-κB pathway" @default.
• W2337582785 cites W1508586558 @default.
• W2337582785 cites W1563636698 @default.
• W2337582785 cites W1606484758 @default.
• W2337582785 cites W1969137895 @default.
• W2337582785 cites W1971402898 @default.
• W2337582785 cites W1972484042 @default.
• W2337582785 cites W1997084308 @default.
• W2337582785 cites W2014663062 @default.
• W2337582785 cites W2019788071 @default.
• W2337582785 cites W2029618334 @default.
• W2337582785 cites W2034882037 @default.
• W2337582785 cites W2040308106 @default.
• W2337582785 cites W2040993067 @default.
• W2337582785 cites W2044825069 @default.
• W2337582785 cites W2045136333 @default.
• W2337582785 cites W2045247817 @default.
• W2337582785 cites W2073880574 @default.
• W2337582785 cites W2074150439 @default.
• W2337582785 cites W2076583198 @default.
• W2337582785 cites W2079144200 @default.
• W2337582785 cites W2091206651 @default.
• W2337582785 cites W2104268053 @default.
• W2337582785 cites W2112996164 @default.
• W2337582785 cites W2114865203 @default.
• W2337582785 cites W2116391331 @default.
• W2337582785 cites W2131574772 @default.
• W2337582785 cites W2139900107 @default.
• W2337582785 cites W2150897565 @default.
• W2337582785 cites W2159114004 @default.
• W2337582785 cites W2169379435 @default.
• W2337582785 cites W2170108839 @default.
• W2337582785 cites W2319528739 @default.
• W2337582785 cites W2330763029 @default.
• W2337582785 doi "https://doi.org/10.3892/mmr.2016.5165" @default.
• W2337582785 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27109343" @default.
• W2337582785 hasPublicationYear "2016" @default.
• W2337582785 type Work @default.
• W2337582785 sameAs 2337582785 @default.
• W2337582785 citedByCount "15" @default.
• W2337582785 countsByYear W23375827852016 @default.
• W2337582785 countsByYear W23375827852018 @default.
• W2337582785 countsByYear W23375827852019 @default.
• W2337582785 countsByYear W23375827852020 @default.
• W2337582785 countsByYear W23375827852021 @default.
• W2337582785 countsByYear W23375827852023 @default.
• W2337582785 crossrefType "journal-article" @default.
• W2337582785 hasAuthorship W2337582785A5006938709 @default.
• W2337582785 hasAuthorship W2337582785A5031810904 @default.
• W2337582785 hasAuthorship W2337582785A5057107704 @default.
• W2337582785 hasAuthorship W2337582785A5060282209 @default.
• W2337582785 hasAuthorship W2337582785A5084950552 @default.
• W2337582785 hasBestOaLocation W23375827851 @default.
• W2337582785 hasConcept C100175707 @default.
• W2337582785 hasConcept C104317684 @default.
• W2337582785 hasConcept C121608353 @default.
• W2337582785 hasConcept C126322002 @default.
• W2337582785 hasConcept C127561419 @default.
• W2337582785 hasConcept C147447768 @default.
• W2337582785 hasConcept C1491633281 @default.
• W2337582785 hasConcept C203014093 @default.
• W2337582785 hasConcept C204232928 @default.
• W2337582785 hasConcept C2777730290 @default.
• W2337582785 hasConcept C2779013556 @default.
• W2337582785 hasConcept C2780932548 @default.
• W2337582785 hasConcept C2780983412 @default.
• W2337582785 hasConcept C2781018059 @default.
• W2337582785 hasConcept C29537977 @default.
• W2337582785 hasConcept C502942594 @default.
• W2337582785 hasConcept C526805850 @default.
• W2337582785 hasConcept C55493867 @default.
• W2337582785 hasConcept C62478195 @default.
• W2337582785 hasConcept C71924100 @default.
• W2337582785 hasConcept C76419328 @default.
• W2337582785 hasConcept C86803240 @default.
• W2337582785 hasConcept C95444343 @default.
• W2337582785 hasConceptScore W2337582785C100175707 @default.
• W2337582785 hasConceptScore W2337582785C104317684 @default.
• W2337582785 hasConceptScore W2337582785C121608353 @default.
• W2337582785 hasConceptScore W2337582785C126322002 @default.
• W2337582785 hasConceptScore W2337582785C127561419 @default.
• W2337582785 hasConceptScore W2337582785C147447768 @default.
• W2337582785 hasConceptScore W2337582785C1491633281 @default.
• W2337582785 hasConceptScore W2337582785C203014093 @default.
• W2337582785 hasConceptScore W2337582785C204232928 @default.
• W2337582785 hasConceptScore W2337582785C2777730290 @default.
• W2337582785 hasConceptScore W2337582785C2779013556 @default.
• W2337582785 hasConceptScore W2337582785C2780932548 @default.
• W2337582785 hasConceptScore W2337582785C2780983412 @default.

• next